Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6141-6146

  Tamura, Daisuke ^a,b   Nguyen, Ha T ^a,c   Sleeman, Katrina ^a   Levine, Marnie ^a,c   Mishin, Vasiliy P ^a   Yang, Hua ^a   Guo, Zhu ^a   Okomo Adhiambo, Margaret ^a   Xu, Xiyan ^a   Stevens, James ^a   Gubareva, Larisa V ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^c BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; ISOLEUCINE; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; RECOMBINANT PROTEIN; SIALIDASE; THREONINE; VALINE; ZANAMIVIR; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE SEQUENCE; INFLUENZA A (H3N2); MDCK CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PYROSEQUENCING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; CHEMISTRY; CULTURE TECHNIQUE; DOG; DRUG EFFECTS; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IC50; INFLUENZA VIRUS A H3N2; MDCK CELL LINE; VIRUS LOAD; VIRUS REPLICATION;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; CELL CULTURE TECHNIQUES; CYCLOPENTANES; DOGS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; GENE EXPRESSION; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INHIBITORY CONCENTRATION 50; MADIN DARBY CANINE KIDNEY CELLS; NEURAMINIDASE; OSELTAMIVIR; VIRAL LOAD; VIRAL PROTEINS; VIRUS REPLICATION; ZANAMIVIR;

EID: 84887464932     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01364-13     Document Type: Article

References (35)

1. Centers for Disease Control and Prevention. 2011. Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly. Rep. 60:1-28. http://www.cdc.gov/mmwr/pdf/rr/rr 6001.pdf.
2. World Health Organization. 2010. WHO guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses. World Health Organization, Geneva, Switzerland. http://www .who.int/csr/resources/ publications/swineflu/h1n1-guidelines-pharmaceutical-mngt.pdf.
3. Hersh AL, Maselli JH, Cabana MD. 2009. Changes in prescribing of antiviral medications for influenza associated with new treatment guidelines. Am. J. Public Health 99(Suppl 2):S362-S364.
4. Nguyen HT, Fry AM, Gubareva LV. 2012. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir. Ther. 17:159-173.
5. Govorkova EA, Matrosovich MN, Tuzikov AB, Bovin NV, Gerdil C, Fanget B, Webster RG. 1999. Selection of receptor-binding variants of human influenza A and B viruses in baby hamster kidney cells. Virology 262:31-38.
6. Schepetiuk SK, Kok T. 1993. The use of MDCK, MEK and LLC-MK2 cell lines with enzyme immunoassay for the isolation of influenza and parainfluenza viruses from clinical specimens. J. Virol. Methods 42:241-250.
7. Govorkova EA, Kaverin NV, Gubareva LV, Meignier B, Webster RG. 1995. Replication of influenza A viruses in a green monkey kidney continuous cell line (Vero). J. Infect. Dis. 172:250-253.
8. Govorkova EA, Murti G, Meignier B, de Taisne C, Webster RG. 1996. African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses. J. Virol. 70:5519-5524.
9. Zhirnov OP, Vorobjeva IV, Saphonova OA, Malyshev NA, Ovcharenko AV, Klenk HD. 2007. Specific biochemical features of replication of clinical influenza viruses in human intestinal cell culture. Biochemistry 72: 398-408.
10. Zhirnov OP, Vorobjeva IV, Saphonova OA, Poyarkov SV, Ovcharenko AV, Anhlan D, Malyshev NA. 2009. Structural and evolutionary characteristics of HA, NA, NS andMgenes of clinical influenza A/H3N2 viruses passaged in human and canine cells. J. Clin. Virol. 45:322-333.
11. Zambon, M. 1999. Cell culture for surveillance on influenza. Dev. Biol. Stand. 98:65-74.
12. Meguro H, Bryant JD, Torrence AE, Wright PF. 1979. Canine kidney cell line for isolation of respiratory viruses. J. Clin. Microbiol. 9:175-179.
13. Gaush CR, Smith TF. 1968. Replication and plaque assay of influenza virus in an established line of canine kidney cells. Appl. Microbiol. 16: 588-594.
14. Reina J, Fernandez-Baca V, Blanco I, Munar M. 1997. Comparison of Madin-Darby canine kidney cells (MDCK) with a green monkey continuous cell line (Vero) and human lung embryonated cells (MRC-5) in the isolation of influenza A virus from nasopharyngeal aspirates by shell vial culture. J. Clin. Microbiol. 35:1900-1901.
15. Ito T, Suzuki Y, Takada A, Kawamoto A, Otsuki K, Masuda H, Yamada M, Suzuki T, Kida H, Kawaoka Y. 1997. Differences in sialic acidgalactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection. J. Virol. 71:3357-3362.
16. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. 2006. Avian flu: influenza virus receptors in the human airway. Nature 440:435-436.
17. Barnett JM, Cadman A, Gor D, Dempsey M, Walters M, Candlin A, Tisdale M, Morley PJ, Owens IJ, Fenton RJ, Lewis AP, Claas EC, Rimmelzwaan GF, De Groot R, Osterhaus AD. 2000. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob. Agents Chemother. 44:78-87.
18. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1257-1262.
19. Tisdale M. 2000. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev. Med. Virol. 10:45-55.
20. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. 2003. Overexpression of the alpha-2,6-sialyltransferase inMDCKcells increases influenza virus sensitivity to neuraminidase inhibitors. J. Virol. 77:8418-8425.
21. Hatakeyama S, Sakai-Tagawa Y, Kiso M, Goto H, Kawakami C, Mitamura K, Sugaya N, Suzuki Y, Kawaoka Y. 2005. Enhanced expression of an alpha2,6-linked sialic acid onMDCKcells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J. Clin. Microbiol. 43:4139-4146.
22. Oh DY, Barr IG, Mosse JA, Laurie KL. 2008. MDCK-SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J. Clin. Microbiol. 46:2189-2194.
23. Lin YP, Gregory V, Collins P, Kloess J, Wharton S, Cattle N, Lackenby A, Daniels R, Hay A. 2010. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? J. Virol. 84:6769-6781.
24. Zhu X, McBride R, Nycholat CM, Yu W, Paulson JC, Wilson IA. 2012. Influenza virus neuraminidases with reduced enzymatic activity that avidly bind sialic acid receptors. J. Virol. 86:13371-13383.
25. WHO Global Influenza Surveillance Network. 2011. Manual for the laboratory diagnosis and virological surveillance of influenza. WHO, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2011/9789241 548090-eng.pdf.
26. Hierholzer JC, Killington RA. 1996. Virus isolation and Quantification: detection of viruses in cell cultures in absence of CPE, p 33-35. In Mahy BVJ, KangroHO(ed), Virology methods manual. Academic Press, San Diego, CA.
27. Okomo-Adhiambo M, Sleeman K, Lysen C, Nguyen HT, Xu X, Li Y, Klimov AI, Gubareva LV. 2013. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season. Influenza Other Respi. Viruses 7:645-658.
28. World Health Organization. 2012. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility-Geneva, November 2011 and June 2012. Wkly. Epidemiol. Rec. 87:369-374.
29. Levine M, Sheu TG, Gubareva LV, Mishin VP. 2011. Detection of hemagglutinin variants of the pandemic influenzaA(H1N1) 2009 virus by pyrosequencing. J. Clin. Microbiol. 49:1307-1312.
30. Deyde VM, Okomo-Adhiambo M, Sheu TG, Wallis TR, Fry A, Dharan N, Klimov AI, Gubareva LV. 2009. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res. 81:16-24.
31. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG. 2009. Zanamivirresistant influenza viruses with a novel neuraminidase mutation. J. Virol. 83:10366-10373.
32. Okomo-Adhiambo M, Nguyen HT, Sleeman K, Sheu TG, Deyde VM, Garten RJ, Xu X, Shaw MW, Klimov AI, Gubareva LV. 2010. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res. 85:381-388.
33. World Health Organization. 2010. Preliminary review of D222G amino acid substitution in the haemagglutinin of pandemic influenza A (H1N1) 2009 viruses. Wkly. Epidemiol. Rec. 85:21-28.
34. Colman PM. 1999. A novel approach to antiviral therapy for influenza. J. Antimicrob. Chemother. 44(Suppl B):17-22.
35. Duwe S, Schweiger B. 2008. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1. J. Virol. Methods 153:134-141.